Edition:
United States

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

13.22USD
4:00pm EDT
Change (% chg)

$0.63 (+5.00%)
Prev Close
$12.59
Open
$12.59
Day's High
$13.47
Day's Low
$12.59
Volume
251,282
Avg. Vol
215,469
52-wk High
$19.91
52-wk Low
$8.70

Latest Key Developments (Source: Significant Developments)

Insys Therapeutics announces chief financial officer transition
Tuesday, 16 May 2017 06:50am EDT 

May 16 (Reuters) - Insys Therapeutics Inc :Insys Therapeutics announces chief financial officer transition.Insys Therapeutics Inc - Darryl S. Baker, company's chief financial officer ("CFO"), will transition from role of CFO when a successor is hired.Insys Therapeutics Inc - Insys has engaged an executive search firm to support recruitment of a new CFO.  Full Article

Insys Therapeutics reports Q1 loss per share $0.09
Tuesday, 9 May 2017 06:50am EDT 

May 9 (Reuters) - Insys Therapeutics Inc : :Insys therapeutics reports first quarter 2017 results.Q1 adjusted non-GAAP loss per share $0.09.Q1 loss per share $0.09.Q1 revenue $36 million versus I/B/E/S view $37.8 million.Q1 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.10, revenue view $37.8 million -- Thomson Reuters I/B/E/S.Insys Therapeutics Inc - cash, cash equivalents and investments were $218.5 million as of March 31, 2017.  Full Article

Insys therapeutics accepts resignation of Santosh Vetticaden, interim CEO
Monday, 17 Apr 2017 06:03am EDT 

April 17 (Reuters) - Insys Therapeutics Inc :On April 11, 2017, Insys Therapeutics accepted resignation of Santosh Vetticaden, interim chief executive officer.  Full Article

Insys Therapeutics reports Q4 adjusted earnings of $0.03/shr
Monday, 3 Apr 2017 06:50am EDT 

Insys Therapeutics Inc : Insys Therapeutics reports fourth quarter and year end 2016 results . Q4 adjusted non-GAAP earnings per share $0.03 . Q4 revenue $54.9 million versus I/B/E/S view $51.2 million . Q4 earnings per share view $-0.00 -- Thomson Reuters I/B/E/S . Q4 loss per share $0.05 . Insys Therapeutics Inc - insys management will not hold a conference call for Q4 and full year 2017 . Insys Therapeutics Inc says for Q1 of 2017, company experienced an approximate 32 percent decline in subsys scripts as compared Q4 of 2016 . Insys Therapeutics - Saeed Motahari will become president and chief executive officer and be appointed to board of directors, effective April 17, 2017 . Says for Q1 of 2017, company experienced an approximate 32 percent decline in subsys scripts as compared Q4 of 2016 . Insys Therapeutics Inc says with recent clarity on scheduling of Syndros, targeting a launch in second half of 2017 . Insys Therapeutics Inc says targeting an NDA filing by end-2017 for Buprenorphine Sublingual spray for treatment of moderate to acute pain .Insys Therapeutics - anticipates "commensurate impact" on net revenue for Q1'17 due to decline in subsys scripts seen in Q1'17 compared to Q4'16.  Full Article

Insys Therapeutics to restate some financial statements
Friday, 31 Mar 2017 05:15pm EDT 

Insys Therapeutics Inc : Insys Therapeutics Inc-previously issued interim unaudited financial statements as of and for Sept 30, June 30, March 31, 2016 and 2015, should no longer be relied on . Insys Therapeutics Inc- financial statements as of Sept 30, June 30, and March 31, 2016 and 2015 will be restated due to identification of certain errors .Insys Therapeutics Inc- restatements result from errors related to company's accounting for certain of its product sales allowances.  Full Article

Insys announces Saeed Motahari to become president and CEO
Monday, 27 Mar 2017 07:00am EDT 

Insys Therapeutics Inc : Insys announces saeed motahari to become president and chief executive officer and member of the board of directors effective April 17, 2017 .Insys Therapeutics Inc - effective April 17, Saeed Motahari, will become co's president and ceo, be appointed to company's board of directors.  Full Article

Insys Therapeutics Drug Enforcement Agency issued an interim final rule
Thursday, 23 Mar 2017 07:34am EDT 

Insys Therapeutics Inc : Insys Therapeutics-drug enforcement agency issued interim final rule that would result in syndros being placed in schedule II of Controlled Substances Act .Insys Therapeutics Inc - "look forward to interacting with FDA to finalize labeling and subsequent launch of Syndros in second half of 2017".  Full Article

Insys Therapeutics announces delay in release of Q4, FY 2016 results
Wednesday, 15 Mar 2017 04:30pm EDT 

Insys Therapeutics Inc : Insys Therapeutics announces delay in release of its Q4 and full year 2016 results . Insys Therapeutics Inc - estimates that its net sales during quarter ended December 31, 2016 were approximately $54 million . Insys Therapeutics - audit committee has been conducting independent review of co's processes related to estimation of, increases to, certain sales allowances recorded during 2016 . Insys Therapeutics - as result of review, which is on-going, company does not expect to announce Q4 and full year 2016 financial results on March 16 .Insys Therapeutics - has filed notification of late filing on form 12B-25 with SEC to obtain automatic 15-day extension.  Full Article

Insys Therapeutics announces retirement of Dr. John Kapoor as CEO
Monday, 9 Jan 2017 06:50am EST 

Insys Therapeutics Inc : Insys Therapeutics announces retirement of Dr. John n. Kapoor as ceo and chairman; appoints Dr. Santosh vetticaden as interim CEO and Steven Meyer as chairman of the board .Insys Therapeutics inc - Kapoor will remain a member of board.  Full Article

Insys Therapeutics, Inc. issues statement regarding department of justice press release
Thursday, 8 Dec 2016 03:50pm EST 

Insys Therapeutics Inc : Insys Therapeutics, Inc. Issues statement regarding department of justice press release . Insys Therapeutics Inc - "charges against individuals discussed in doj press release relate to previously disclosed investigations" .Insys Therapeutics Inc - continues to cooperate with all relevant authorities in its ongoing investigations.  Full Article

More From Around the Web